RecruitingChronic Obstructive Pulmonary Disease

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Eligible age

40–90 yrs

Accepts

All genders

Locations

25 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment period in parent studies GB43311 or GB44332.

Sponsor: Hoffmann-La Roche

You may qualify if…

✓ Completion of the 52-week treatment period in either parent GB43311 or GB44332

You may not qualify if…

✕ Withdrawal of consent and/or premature discontinuation from parent study
✕ Any permanent discontinuation of study drug in parent study
✕ Significant non-compliance in the parent study, specifically defined as missing scheduled visits, per investigator's judgment
✕ Any new diagnosis of asthma according to the Global Initiative for Asthma guidelines or other accepted guidelines since enrolling in the parent study
✕ Any new clinically significant pulmonary disease other than COPD (e.g., pulmonary fibrosis, sarcoidosis, chronic pulmonary embolism or primary pulmonary hypertension, alpha-1-antitrypsin deficiency) since enrolling in the parent study
✕ Any new unstable cardiac disease, myocardial infarction, or New York Heart Association Class III or IV heart failure since enrolling in the parent study